About us Become an industry partner
What is the CLL IC Taskforce?
The CLL Immune Challenges Taskforce – CLL IC Taskforce – is a multidisciplinary group of CLL patient advocates, clinicians, researchers and industry parteners from around the world aiming to raise awareness of the impact that CLL immune challenges can have for patients, their families and clinical care teams to drive meaningful change in policy and practice.
Together, we can overcome immune challenges and enhance the quality of life for all people affected by CLL.
How was the CLL IC Taskforce established?
The CLL IC Taskforce aims to build upon the legacy of the 2023 white paper, “Compromised: Uncovering the Immune-Related Challenges Facing People with Chronic Lymphocytic Leukaemia”, a collaboration between AstraZeneca and CLLAN. This foundational document has inspired and shaped the CLL IC Taskforce’s at every step.
To shape and co-develop the CLL IC Taskforce with the CLL community, several steps were taken across 2024:
Step-1 Virtual workshops
In July 2024, CLLAN hosted two virtual workshops which gathered 32 experts from 19 countries across the globe, including leading voices from the clinical and patient advocacy communities. During the workshops, participants engaged in rich discussions about policy and advocacy priorities which could be taken forward by the CLL IC Taskforce.
The workshops were kindly supported by AstraZeneca and Takeda, setting the stage for a multi-funded approach moving forward.
Step-2 Consensus building
Workshop participants engaged in a prioritisation exercise in autumn 2024 and discussions within the clinical and advocacy communities in January and February 2025. These engagements aimed to allow the community to prioritise and refine the CLL IC Taskforce’s activities and work plan for 2025-2026.
Who is involved?
The CLL IC Taskforce is driven by its members from around the globe. Membership is voluntary, open to all and includes patient advocates and healthcare professionals from around the world with support from AstraZeneca, Takeda, Johnson & Johnson and Lilly.
Come back soon to find out more about our Steering Committee, working group members and the task force Terms Of Reference.
Our work
The CLL IC Taskforce is committed to driving meaningful change through collaborative projects and initiatives. In 2025 and 2026, we will focus on:
- Quality of life
- Clinical best practice
Come back soon to find out more about our workstreams.
Want to become involved?
The success of the CLL IC Taskforce will rely on collaboration across the community.
Are you a clinician, clinical researcher or a patient advocate with a special interest in CLL?
Clinicians and patient advocates are at the heart of our Taskforce. Your firsthand experience and evidence is invaluable to our work, and your involvement ensures that our efforts remain focused on real-world impact and person-centred outcomes. Please get in touch with Jan and the CLL IC Secretariat should you wish to become a member.
Are you a potential industry partner?
Joining our Taskforce as an industry partner offers a unique opportunity to improve CLL care and patient experiences. As a valued partner, you will play a significant role in driving our initiatives forward and contributing to meaningful change. To find out more about the benefits of becoming an industry partner, please click here.
Want to join the CLL IC Taskforce?
Contact us:
Jan Rynne
Project and Stakeholder Relations
Email: jan@clladvocates.net
Secretariat
CLL IC Taskforce
Email: CLLICTaskforce@mhpgroup.com